| Title | Human Psychopharmacology |
| Abbreviation | Hum. Psychopharmacol. |
| Publication Type | Journal |
| Subject Area, Categories, Scope | Neurology (Q3); Neurology (clinical) (Q3); Pharmacology (medical) (Q3); Psychiatry and Mental Health (Q3) |
| h-index | 86 |
| Overall Rank/Ranking | 10002 |
| SCImago Journal Rank (SJR) | 0.541 |
| Impact Score | 1.98 |
| Publisher | John Wiley and Sons Ltd |
| Country | United Kingdom |
| ISSN | 10991077, 08856222 |
| Best Quartile | Q3 |
| Coverage History | 1986-2023 |
Human Psychopharmacology: Clinical and Experimental provides a forum for the evaluation of clinical and experimental research on both new and established psychotropic medicines. Experimental studies of other centrally active drugs, including herbal products, in clinical, social and psychological contexts, as well as clinical/scientific papers on drugs of abuse and drug dependency will also be considered. While the primary purpose of the Journal is to publish the results of clinical research, the results of animal studies relevant to human psychopharmacology are welcome.
Human Psychopharmacology is a journal covering the technologies/fields/categories related to Neurology (Q3); Neurology (clinical) (Q3); Pharmacology (medical) (Q3); Psychiatry and Mental Health (Q3). It is published by John Wiley and Sons Ltd. The overall rank of Human Psychopharmacology is 10002. According to SCImago Journal Rank (SJR), this journal is ranked 0.541. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come. SJR acts as an alternative to the Journal Impact Factor (or an average number of citations received in last 2 years). This journal has an h-index of 86. The best quartile for this journal is Q3.
The ISSN of Human Psychopharmacology journal is 10991077, 08856222. An International Standard Serial Number (ISSN) is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic. Human Psychopharmacology is cited by a total of 246 articles during the last 3 years (Preceding 2023).
The Impact IF 2023 of Human Psychopharmacology is 1.98, which is computed in 2024 as per its definition. Human Psychopharmacology IF is increased by a factor of 0.28 and approximate percentage change is 16.47% when compared to preceding year 2022, which shows a rising trend. The impact IF, also denoted as Journal impact score (JIS), of an academic journal is a measure of the yearly average number of citations to recent articles published in that journal. It is based on Scopus data.
Impact IF 2023 of Human Psychopharmacology is 1.98. If the same upward trend persists, Impact IF may rise in 2024 as well.
| Year | Impact IF |
|---|---|
| 2023/2024 | Coming Soon |
| 2023 | 1.98 |
| 2022 | 1.70 |
| 2021 | 2.40 |
| 2020 | 1.45 |
| 2019 | 2.20 |
| 2018 | 2.27 |
| 2017 | 2.89 |
| 2016 | 2.58 |
| 2015 | 3.03 |
| 2014 | 2.64 |
Human Psychopharmacology has an h-index of 86. It means 86 articles of this journal have more than 86 number of citations. The h-index is a way of measuring the productivity and citation impact of the publications. The h-index is defined as the maximum value of h such that the given journal/author has published h papers that have each been cited at least h number of times.
The ISSN of Human Psychopharmacology is 10991077, 08856222. ISSN stands for International Standard Serial Number.
An ISSN is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic.
The overall rank of Human Psychopharmacology is 10002. According to SCImago Journal Rank (SJR), this journal is ranked 0.541. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come.
| Year | SJR |
|---|---|
| 2023/2024 | Coming Soon |
| 2023 | 0.541 |
| 2022 | 0.449 |
| 2021 | 0.448 |
| 2020 | 0.461 |
| 2019 | 0.714 |
| 2018 | 0.657 |
| 2017 | 1.128 |
| 2016 | 1.018 |
| 2015 | 0.974 |
| 2014 | 0.818 |
| Year | Ranking |
|---|---|
| 2023/2024 | Coming Soon |
| 2023 | 10002 |
| 2022 | 11356 |
| 2021 | 11035 |
| 2020 | 10789 |
| 2019 | 6816 |
| 2018 | 7346 |
| 2017 | 3682 |
| 2016 | 4314 |
| 2015 | 4605 |
| 2014 | 5574 |
Human Psychopharmacology is published by John Wiley and Sons Ltd. It's publishing house is located in United Kingdom. Coverage history of this journal is as following: 1986-2023. The organization or individual who handles the printing and distribution of printed or digital publications is known as Publisher.
Visit the official website of the journal/conference to check the further details about the call for papers.
The IS0 4 standard abbreviation of Human Psychopharmacology is Hum. Psychopharmacol.. This abbreviation ('Hum. Psychopharmacol.') is well recommended and approved for the purpose of indexing, abstraction, referencing and citing goals. It meets all the essential criteria of ISO 4 standard.
ISO 4 (International Organization for Standardization 4) is an international standard that defines a uniform and consistent system for abbreviating serial publication titles and journals.
If your research field is/are related to Neurology (Q3); Neurology (clinical) (Q3); Pharmacology (medical) (Q3); Psychiatry and Mental Health (Q3), then please visit the official website of this journal.
The acceptance rate/percentage of any academic journal/conference depends upon many parameters. Some of the critical parameters are listed below.
It is essential to understand that the acceptance rate/rejection rate of papers varies among journals. Some Journals considers all the manuscripts submissions as a basis of acceptance rate computation. On the other hand, few consider the only manuscripts sent for peer review or few even not bother about the accurate maintenance of total submissions. Hence, it can provide a rough estimation only.
The best way to find out the acceptance rate is to reach out to the associated editor or to check the official website of the Journal/Conference.
Human Psychopharmacology latest impact IF is 1.98. It's evaluated in the year 2023. The highest and the lowest impact IF or impact score of this journal are 3.03 (2015) and 1.45 (2020), respectively, in the last 10 years. Moreover, its average IS is 2.31 in the previous 10 years.
The Human Psychopharmacology has an SJR (SCImago Journal Rank) of 0.541, according to the latest data. It is computed in the year 2024. In the past 10 years, this journal has recorded a range of SJR, with the highest being 1.128 in 2017 and the lowest being 0.448 in 2021. Furthermore, the average SJR of the Human Psychopharmacology over the previous 10-year period stands at 2.31.
The latest h-index of the Human Psychopharmacology is 86.
The Human Psychopharmacology is published by the John Wiley and Sons Ltd, with its country of publication being the United Kingdom.
The Human Psychopharmacology is currently ranked 10002 out of 27955 Journals, Conferences, and Book Series in the latest ranking. Over the course of the last 10 years, this journal has experienced varying rankings, reaching its highest position of 3682 in 2017 and its lowest position of 11356 in 2022.
The standard ISO4 abbreviation for the Human Psychopharmacology is Hum. Psychopharmacol..
Human Psychopharmacology is classified as a journal that the John Wiley and Sons Ltd publishes.
The Human Psychopharmacology encompasses the following areas:
For a more comprehensive understanding of its scope, check the official website of this journal.
The Human Psychopharmacology is assigned the following International Standard Serial Numbers (ISSN): 10991077, 08856222.
The best quartile for the Human Psychopharmacology is Q3 (2023).
The Human Psychopharmacology coverage history can be summarized as follows: 1986-2023.
| Journal/Conference/Workshop/Book Title | Type | Ranking | Publisher | h-index | Impact Score |
|---|---|---|---|---|---|
| Journal of Business Economics and Management | journal | 9513 | Vilnius Gediminas Technical University | 48 | 3.30 |
| SPE Production and Operations Symposium, Proceedings | conference and proceedings | 15907 | 21 | 0.00 | |
| Clinical Medicine and Research | journal | 14722 | Marshfield Clinic | 62 | 1.02 |
| Journal of Geriatric Physical Therapy | journal | 9578 | Lippincott Williams and Wilkins Ltd. | 47 | 1.23 |
| IEEE/OSA Journal of Display Technology | journal | 12809 | IEEE Computer Society | 68 | 0.00 |
| Howard Journal of Communications | journal | 10151 | Taylor and Francis Ltd. | 39 | 1.66 |
| Natural Solutions | trade journal | 28581 | Innovision Health Media | 1 | 0.00 |
| Consulting engineer Barrington | journal | 24079 | Cahners Pub. Co. | 0 | 0.00 |
| Metascience | journal | 24313 | Springer Nature | 3 | 0.00 |
| East African journal of public health | journal | 19634 | East African Public Health Association | 23 | 0.00 |
| Year | Impact Score (IS) |
|---|---|
| 2024/2025 | Coming Soon |
| 2023 | 1.98 |
| 2022 | 1.70 |
| 2021 | 2.40 |
| 2020 | 1.45 |
| 2019 | 2.20 |
| 2018 | 2.27 |
| 2017 | 2.89 |
| 2016 | 2.58 |
| 2015 | 3.03 |
| 2014 | 2.64 |
